Distinguishing Pancreatic Cancer from Benign Pancreatic Disease using Nanoparticle-based Biomarkers

使用基于纳米颗粒的生物标志物区分胰腺癌和良性胰腺疾病

基本信息

  • 批准号:
    10363335
  • 负责人:
  • 金额:
    $ 47.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-01 至 2026-12-31
  • 项目状态:
    未结题

项目摘要

Project Summary This project evaluates the efficacy of using biomarkers carried by tumor-derived exosomes and other organelle- derived extracellular vesicles to differentiate patients with pancreatic cancer from patients with benign pancreatic disease. We will use high conductance dielectrophoresis-based technology to simultaneously recover different types of these cancer-derived nanoparticles from individual samples of volume limited patient plasma. This will enable access to volume restricted early stage cancer samples. This research will generate new knowledge supporting the development of a nanoparticle-based biomarker panel for early and late stage pancreatic cancer detection and will support the rationale to bring nanoparticle-based diagnostics to the clinical setting. Pancreatic cysts are coincidently discovered with increasing frequency as the use of high resolution CT and MRI imaging increases, with up to 9.3% of patients having an asymptomatic cyst. An invasive endoscopic ultrasound guided fine needle aspiration biopsy (EUS/FNA) is traditionally used to determine if the cyst is pancreatic ductal adenocarcinoma (PDAC). This has a high financial cost and associated health risk where 1/100 patients will develop acute pancreatitis and 1/10 of these patients will die. Currently 60-76% of patients that undergo EUS/FNA do not have pancreatic cancer. This signifies the unmet clinical need to develop a blood test to stratify patients with pancreatic cysts into categories of high-probability and low-probability for having PDAC, where high-probability would benefit from the EUS/FNA. Currently, no blood based PDAC biomarkers exist. Tumor- derived nanoparticles offer a new source of potential PDAC related biomarkers. The challenge is that traditional nanoparticle recovery methods for each nanoparticle type require plasma volumes that are too large to be supported with currently available PDAC patient plasma samples. Our preliminary data now suggest that high conductance dielectrophoresis (DEP) techniques can recover sufficient amounts of nanoparticle derived biomarkers to detect precancerous lesions as well as differentiate early and late stage PDAC from controls and requires only 30 µl of plasma. Each Aim will translate our DEP validation of individual biomarkers into a panel that will be evaluated in a blinded cohort study consisting of patients with PDAC and benign pancreatic disease. We focus Aim 1 on particles actively released by tumors, and Aim 2 on different cellular organelle fragments. Aim 3 evaluates these biomarkers, and five from our preliminary data, on stage 1 and 2 PDAC samples. The significance of this research is that the knowledge generated will lead to potential validation of a panel of nanoparticle-associated biomarkers capable of differentiating PDAC from benign pancreatic disease. The research proposed here may ultimately support the rationale for the clinical development of a nanoparticle-based diagnostic blood test to identify patients with pancreatic cysts that would benefit from the EUS/FNA procedure.
项目摘要 该项目评估了使用肿瘤源性外泌体和其他细胞器携带的生物标志物的有效性, 衍生的细胞外囊泡,以区分胰腺癌患者和良性胰腺癌患者。 疾病我们将使用高电导率双稳态技术, 这些癌症衍生的纳米颗粒的类型来自体积有限的患者血浆的个体样品。这将 能够获得体积受限的早期癌症样本。这项研究将产生新的知识 支持开发用于早期和晚期胰腺癌的基于纳米颗粒的生物标志物组 检测,并将支持将基于纳米颗粒的诊断带到临床环境的基本原理。 随着高分辨率CT和MRI的应用,胰腺囊肿的发现率越来越高 影像学检查结果显示,高达9.3%的患者有无症状的囊肿。有创超声内镜 传统上使用引导细针穿刺活检(EUS/FNA)来确定囊肿是否为胰腺导管 腺癌(PDAC)。这具有很高的财务成本和相关的健康风险,其中1/100的患者将 发生急性胰腺炎,这些患者中有1/10会死亡。目前,60-76%的患者接受 EUS/FNA没有胰腺癌。这意味着开发一种血液测试来分层 胰腺囊肿患者分为高概率和低概率PDAC,其中 高概率将受益于EUS/FNA。目前,不存在基于血液的PDAC生物标志物。肿瘤- 衍生的纳米颗粒提供了潜在的PDAC相关生物标志物的新来源。挑战在于传统的 用于每种纳米颗粒类型的纳米颗粒回收方法需要太大的等离子体体积, 支持当前可用的PDAC患者血浆样本。我们的初步数据显示, 电导介电电泳(DEP)技术可以回收足够量的纳米颗粒衍生物, 检测癌前病变以及区分早期和晚期PDAC与对照组的生物标志物, 只需要30微升血浆。每个Aim将把我们对单个生物标志物的DEP验证转化为一个面板 将在由PDAC和良性胰腺疾病患者组成的盲态队列研究中进行评估。 我们将目标1集中在肿瘤主动释放的颗粒上,目标2集中在不同的细胞器片段上。 目的3评估这些生物标志物,以及来自我们初步数据的5个,在第1阶段和第2阶段PDAC样品上。 这项研究的意义在于,所产生的知识将导致一个小组的潜在验证, 纳米颗粒相关的生物标志物能够区分PDAC与良性胰腺疾病。的 这里提出的研究可能最终支持基于纳米颗粒的临床开发的基本原理。 诊断性血液检查,以确定胰腺囊肿患者将受益于EUS/FNA程序。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stuart Duncan Ibsen其他文献

Stuart Duncan Ibsen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stuart Duncan Ibsen', 18)}}的其他基金

Distinguishing Pancreatic Cancer from Benign Pancreatic Disease using Nanoparticle-based Biomarkers
使用基于纳米颗粒的生物标志物区分胰腺癌和良性胰腺疾病
  • 批准号:
    10542739
  • 财政年份:
    2022
  • 资助金额:
    $ 47.17万
  • 项目类别:

相似海外基金

Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
  • 批准号:
    23K08495
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
  • 批准号:
    10719777
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
  • 批准号:
    22KJ2498
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
  • 批准号:
    10726042
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
  • 批准号:
    10607151
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
  • 批准号:
    23H03765
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
  • 批准号:
    23K08075
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
  • 批准号:
    10720034
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
  • 批准号:
    2306943
  • 财政年份:
    2023
  • 资助金额:
    $ 47.17万
  • 项目类别:
    Standard Grant
Towards Achieving Zero Emissions through the use of an Environmentally Benign Non-Regenerable Solvent to Capture CO2 from Large Point Source Emitters for Direct Permanent Storage in Geological Formation or Usage in Accelerated Curing of Ready-mix Con
通过使用环境友好的不可再生溶剂从大型点源排放器捕获二氧化碳,直接永久储存在地质构造中或用于预拌混凝土的加速固化,从而实现零排放
  • 批准号:
    RGPIN-2022-03431
  • 财政年份:
    2022
  • 资助金额:
    $ 47.17万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了